Oncolytic viruses have been taking the front stage in biological therapy for cancer recently.
The first and most potent virus to be used in oncolytic virotherapy is human adenovirus …

Twenty years of oncolytic virus development have created a field that is driven by the
potential promise of lasting impact on our cancer treatment repertoire. With the field …

Tumor-selectively replicating (oncolytic) viruses are promising tools for therapy of solid
cancers and have been initially developed to achieve potent tumor lysis with acceptable …

Adenoviruses (Ad) are commonly used both experimentally and clinically, including
oncolytic virotherapy applications. In the clinical area, efficacy is frequently hampered by the …

Despite setbacks in the past and apparent hurdles ahead, gene therapy is advancing toward
reality. The past several years have witnessed this new field of biomedicine developing …

Achieving high efficiency, targeted gene delivery with adenoviral vectors is a long-standing
goal in the field of clinical gene therapy. To achieve this, platform vectors must combine …

Adenoviral gene therapy is an exciting novel approach for treating cancers resistant to
currently available therapies. However, currently there is little evidence supporting …

Myocardial angiogenesis mediated by human vascular endothelial growth factor 165
(hVEGF 165) cDNA was promoted in rat myocardium using an in vivo-targeted gene delivery …

E2F acts as a transcriptional repressor when bound to unphosphorylated RB during the G 1
or G 0 phase. Upon phosphorylation, E2F is released from the E2F–RB complexes to …

Bladder-related diseases are among the most common and costly to the healthcare system,
and therefore require new approaches to treatment. Organoids and spheroids are 3D …